MAVATREP

Antagonist of TRPV1

Structure

SERP Rating

Probe MAVATREP is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

TRPV1

Antagonist

up to 1 uM

Probe Availability:

MedChemExpress
MCULE

In Vitro Validations

No in Vitro Validations

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Probe Selectivity in Vitro:

In cytochrome P450 isoenzyme studies in human liver microsomes, Mavatrep exhibited minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6. In a panel of 50 G protein-coupled receptor and ion channel binding assays, 1 μM Mavatrep did not exhibit greater than 50% inhibition of radioligand binding to any of the targets. In a panel of 190 kinase assays, Mavatrep did not exhibit any inhibition of activity. In a recombinant hERG channel assay, 10 μM Mavatrep exhibited no inhibition of [H3]-astemizole binding.

I have extra information to add

SERP ratings and comments

No SERP comments found for MAVATREP